Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Corbus Pharmaceuticals stock: An explosive 342% YTD surge

Corbus Pharmaceuticals stock price

Shares of Corbus Pharmaceuticals (NASDAQ: CRBP) have already experienced a meteoric rise of over 300% year-to-date. This is thanks to fresh news released two Fridays ago, on January 26. The company released early but promising data from its Phase 1 trial involving cancer patients treated with its antibody-drug conjugate CRB-701.

This particular drug conjugate stands among three pivotal drugs currently undergoing clinical trial phases, but its progress has notably accelerated in terms of anticipated approval prospects, supported by these promising results. 

With the recent groundbreaking news and the remarkable surge in price, trading volume, and overall company valuation, let's delve deeper into this recent standout performer to assess whether it represents a potential investment opportunity or if it might be experiencing an overvaluation.

What is Corbus Pharmaceuticals?

Corbus Pharmaceuticals stock outlook chart

Corbus Pharmaceuticals Holdings is a biopharmaceutical company dedicated to combating severe illnesses. The company is actively developing several products, including CRB-701, an antibody-drug conjugate (ADC) designed to target Nectin-4 expression on cancer cells, currently undergoing Phase I clinical trials. 

Additionally, CRB-601, an anti-integrin monoclonal antibody, is being developed to block the activation of TGFß expressed on cancer cells to treat solid tumors. Moreover, CRB-913, an endocannabinoid small molecule drug, is being developed for treating obesity and related metabolic diseases.

The company operates under a licensing agreement with Jenrin Discovery, LLC, enabling the development and commercialization of licensed products, including the Jenrin library, which consists of approximately 600 compounds and multiple issued and pending patent filings.

The company’s stock has an average daily volume of 2.25 million shares and a market capitalization of approximately $118 million. Thanks to the recent catalyst and price action, the stock is now up 335% over the previous month and trading near the high-end of its 52-week range. 

Recent developments spark a turnaround for the company

For Corbus, these results couldn't have come at a better time. Despite a lackluster performance in its long-term chart, helped mainly by pandemic-induced optimism, the company now finds itself on the cusp of a potential resurgence. The absence of severe safety events coupled with strong efficacy signals from CRB-701 has reignited investor interest, providing a glimmer of hope for those who've weathered the storm with this biotech player.

Corbus' CEO has emphasized the potential superiority of CRB-701 in treating cervical cancer tumors compared to existing options, hinting at meaningful benefits for both patients and the company. This narrative has captivated the market's attention, positioning CRBP stock as one to watch closely in the months ahead as further trials unfold.

In parallel with this surge, adopting a cautious approach is imperative, recognizing the inherent risks associated with investing in clinical-stage biotech companies. While the recent developments signal a promising trajectory for Corbus Pharmaceuticals, prudent risk management remains paramount amidst the potential for short-term volatility in the stock.

Analysts are bullish, and insiders are buying

Analysts have maintained a bullish outlook on the stock for several months since coverage commenced, consistently assigning it a Buy rating. Currently, two analyst ratings support this sentiment. Following the recent catalyst, analysts at Oppenheimer took proactive measures by substantially increasing their target for CRBP. Oppenheimer analysts raised their target from $20 to $51, anticipating a remarkable 123.68% upside potential at the time of the report.

In addition to the optimistic views shared by analysts, recent insider activity further signals positive prospects for the company and its investors. Notably, in the past twelve months, no insider selling has been recorded. On the contrary, insider purchases totaling over $9 million have been documented during this period. That purchasing occurred following the recent news on January 26, with Cormorant Asset Management, LP, a significant company shareholder, purchasing 282,632 shares at an average price of $32.24. This transaction amounted to a total investment of $9,112,055.68.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.